摘要
目的探究阿仑膦酸钠联合骨化三醇治疗对绝经后女性糖尿病伴骨质疏松症(OP)患者动脉硬化的影响。方法将2011年2月至2013年6月期间内60例绝经后女性糖尿病伴骨质疏松症患者纳入本次研究,随机均衡分为研究组、对照组,每组30例。研究组选择阿仑膦酸钠联合骨化三醇治疗,对照组单纯采用骨化三醇进行治疗,治疗周期持续12个月。治疗后检测患者动脉硬化相关指标,对两种治疗方式进行比较。结果治疗前,两组中膜厚度(IMT)、斑块评分(PS)数据差异无统计学意义(t=0.310,P>0.05;t=0.263,P>0.05)。研究组治疗后IMT、PS较治疗前均无显著性变化(P>0.05),对照组治疗后IMT、PS较治疗前显著增加(P<0.05),且研究组治疗后的IMT、PS均较对照组的低(t=3.297,P<0.05,t=3.590,P<0.05)。治疗1年后,研究组IMT进展患者比率为10.00%(3/30),低于对照组53.33%(16/30),差异有统计学意义(χ2=11.091,P<0.05);研究组PS进展患者比率为16.67%(5/30),明显低于对照组66.67%(20/30),差异有显著性(χ2=15.429,P<0.05)。结论阿仑膦酸钠联合骨化三醇治疗可有效延缓绝经后糖尿病合并骨质疏松患者动脉粥样硬化进展,值得进一步推广应用。
Objective To explore the influence of arteriosclerosis in postmenopausal women with diabetes and osteoporosis by alendronate sodium with rocalirol. Methods 60 cases of postmenopausal women with diabetes and osteoporosis during February 2011 to June 2013 were selected in this study. All patients were divided into research group and control group at random,each 30 cases. The patients of research group received the treatment of Alendronate Sodium with rocalirol,the control group received the treatment of rocalirol,treatment cycle lasted for 12 months. After treatment,atherosclerosis related indicators were tested and compared. Results Before treatment,film thickness,plaque score of two groups had no statistically significant difference（ t = 0. 310,P 〉0. 05; t = 0. 263,P〉 0. 05）. The IMT,PS in research group between after treatment and before treatment had no significant difference（ P〉 0. 05）. The IMT,PS after treatment in control group increased significantly than before treatment（ P〈 0. 05）. The IMT,PS after treatment in research group were lower than that in the control group（ t = 3. 297,P〈 0. 05,t = 3. 590,P〈 0. 05）. After treatment of 1 year,3 cases（ 10. 00%） of research group had progress,16 cases（ 53. 33%） in the control group had for progress. The difference was statistically significant（ χ2= 11. 091,P〈 0. 05）. 5 cases（ 16. 67%） in the plaque integral（ PS） had for progress,20 cases（ 66. 67%） in the control group had progression,with significant difference（ χ2= 15. 429,P〈 0. 05）. Conclusion Alendronate sodium with rocalirol can effectively delay progress of arteriosclerosis in postmenopausal women with diabetes and osteoporosis. The application in clinical is widespread,is worthy of further promotion.
出处
《临床和实验医学杂志》
2015年第22期1873-1875,共3页
Journal of Clinical and Experimental Medicine
